EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)

Yong Jae Lee iD, Yoo-Young Lee iD, Jeong-Yeol Park iD, Hyun-Woong Cho iD, Myong Cheol Lim iD, Mi Kyung Kim iD, Jong-Min Lee iD, Jung-Yun Lee iD

Journal of Gynecologic Oncology · 2025 · 36 (3)

DOI: 10.3802/jgo.2025.36.e35 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Yong Jae Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Endometrial Neoplasms, Immune Checkpoint Inhibitors, Nivolumab. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mismatch repair deficient (MMRd) tumors are known to be highly immunogenic and of great interest for immune checkpoint inhibitor. However, there is no data about the complete response (CR) rate of programmed cell death protein 1 (PD-1) blockade and surgery in subjects with MMRd surgically resectable endometrial cancer. In this regard, we suggest a window of opportunity study of induction PD-1 blockade (nivolumab) in patients with surgically resectable MMRd endometrial cancer. METHODS: This is a multicenter, single-arm phase II trial. A total of 30 surgically resectable MMRd endometrial cancer patients will be enrolled. Inclusion criteria include clinical stage I-IIIC2, tumor specimen that demonstrates MMRd by immunohistochemistry or microsatellite instability. Exclusion criteria include multiple primary cancers, residual adverse effects of prior therapy or effects of surgery. Patients are treated with nivolumab 480 mg intravenously every 4 weeks up to 6 months followed by standard surgery and/or adjuvant treatment. The primary endpoint of the study is clinical CR rate or pathological CR rate after treatment of nivolumab. Secondary endpoints include objective response rate, progression-free survival, overall survival, and adverse events. Correlative studies include genomic characterization of tumors, assessment of immune infiltration of tumor microenvironment, and serial circulating cell-free DNA and immune biomarkers. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05795244.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalEndometrial NeoplasmsImmune Checkpoint InhibitorsNivolumabProgrammed Cell Death 1 ReceptorAgedFemaleHumansMiddle AgedClinical Trials, Phase II as TopicDNA Mismatch RepairMicrosatellite InstabilityBrain NeoplasmsNeoplastic Syndromes, HereditaryColorectal Neoplasms

Stichwörter der Autor:innen

Endometrial CancerMismatch Repair DeficiencyPD-L1 Inhibitor

Substanzen

Antineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsNivolumabPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
  • Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea.
  • Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.
  • Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine, Seoul, Korea.

ORCID-Profile: Yong Jae Lee, Yoo-Young Lee, Jeong-Yeol Park, Hyun-Woong Cho, Myong Cheol Lim, Mi Kyung Kim, Jong-Min Lee, Jung-Yun Lee

Zitieren

APA

Lee, Y. J., Lee, Y. Y., Park, J. Y., Cho, H. W., Lim, M. C., Kim, M. K., Lee, J. M., & Lee, J. Y. (2025). A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC). Journal of Gynecologic Oncology, 36(3). https://doi.org/10.3802/jgo.2025.36.e35

Vancouver

Lee YJ, Lee YY, Park JY, Cho HW, Lim MC, Kim MK, et al. A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC). Journal of Gynecologic Oncology. 2025;36(3). doi:10.3802/jgo.2025.36.e35

BibTeX
@article{Lee2025,
  author = {Lee, Yong Jae and Lee, Yoo-Young and Park, Jeong-Yeol and Cho, Hyun-Woong and Lim, Myong Cheol and Kim, Mi Kyung and Lee, Jong-Min and Lee, Jung-Yun},
  title = {A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)},
  journal = {Journal of Gynecologic Oncology},
  year = {2025},
  volume = {36},
  number = {3},
  doi = {10.3802/jgo.2025.36.e35}
}
Kostenlos starten →